

TreeScan[™]: A Novel Data-Mining Tool for Medical Product Safety Surveillance

Martin Kulldorff

Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School

Azadeh Shoaibi

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Rima Izem

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Judith C. Maro

Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute



ICPE Disclosures

- Funding source: U.S. Food and Drug Administration
 - Under contract: FDA HHSF223201400030I, Task Order: HHSF22301003T
- No relationships to disclose
- The views expressed are the authors' and not necessarily those of the Food and Drug Administration, or the Department of Health and Human Services



Agenda


- Overview of Tree-based Scan Statistics
- TreeScan in Vaccine Safety Surveillance
- TreeScan in Drug Safety Surveillance
- Q&A
- Interactive Demonstration of TreeScan[™] Software
- Signal Detection Exercise
- Q&A



Overview of Tree-based Scan Statistics

Martin Kulldorff

Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School




How can we detect unsuspected adverse reactions? How can we try to ensure that there are no unknown adverse reactions?



TreeScan Data Mining







info@sentinelsystem.org



Goal of TreeScan Method:

Close to complete ascertainment of adverse events

- Find known adverse reactions
- Find any additional adverse reactions , if they exist
- Few false positives, or else, easily explained false positives
- Sufficient sample size to detect very rare adverse reactions



Three Key Issues

- Granularity
- Adjusting for Multiple Testing
- Choice of Comparison Group




Level of Granularity

Is there increased risk for a very specific diagnosis (acute liver failure), or for a range of related diagnoses (any liver problems)?





A Small Three-Level Tree





Lowest Level: ~6000 ICD-9-CM Codes





Some Diagnoses Removed

- Accidents
- Well-care visits
- Common infectious disease
- Cancer and other chronic diseases
- Pregnancy
- Fever





TreeScan Adjusts for Multiple Testing





Temporal Scan Statistic Fixed Window Size






Naus, J Am Stat Assoc, 1965



Temporal Scan Statistic Variable Window Size







Scanning Risk Window

Follow-Up Period: 1-56 days Risk Window Start Range: 1-28 days after vaccination Risk Window End Range: 2-42 days after vaccination Minimum Length: 2 days, Maximum Length: 28 days



A few of the 665 potential risk windows evaluated: [1-5], [2-28], [3-4], [5-12], [7-10], [15-42], [28-34]

Note: Day 0 is not included



Comparison Window

Those days 1-56 after vaccination that are not in the risk window





Tree-Based Scan Statistic

- For each leaf, note the observed number of adverse events in each of the risk and control windows.
- For each higher level branch, add the observed number of events of its leaves.







Tree-Based Scan Statistic

- 1. Scan the tree by considering all possible cuts on any branch, and all possible risk wndows.
- 1. 2. For each cut and risk window, calculate the likelihood.
- 3. Denote the cut/window with the maximum likelihood
- 3. as the most likely cut (cluster).
- 4. 4. Generate 9999 Monte Carlo replications under H₀.
- 5. 5. Compare the most likely cut from the real data set
- 6. with the most likely cuts from the random data sets.

info@sentinels@emlefgthe rank of the most likely cut from the real data 19



What is a TreeScan "Alert"?

- A statistically significant finding of greater than expected occurrence of an exposure-outcome pair
- Signal Detection or Screening Analysis <u>ONLY</u>
 - Produces hypotheses just as FAERS does
- Signal evaluation studies required for any further investigation



TreeScan[™] in Vaccine Safety Surveillance

Azadeh Shoaibi

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration




Data-Mining Designs with Trees

- Exposure-Oriented 1 Exposure: N Outcomes
 - Uses Multi-Level Clinical Classification System (MLCCS) where N=6000+

- Outcome-Oriented M Exposures: 1 Outcome
 - Uses Medi-Span Therapeutic Classification System (Drug Tree) where M=300,000+

Future - M Exposures: N Outcomes







HPV4 (Gardasil) Pilot

- Medically attended adverse events
- Conditional Tree-Temporal Scan Statistic
- Self-Controlled, adjusting for all fixed (non-time-varying) confounders
- First dose after 9th birthday or enrollment
- 1.9 million doses
- Five health plans



Results, HPV4, Dose 1

MLCCS (ICD9)	Disease Name	Win- dow	Obs	AR/ 100K	P=
12		2.4	24.4	2.0	0.0010
12	Diseases of skin and subcutaneous tissue	2-4	214	3.8	
12.01	Skin and subcutaneous tissue infections	2-4	111	2.3	0.04
12.01.01	Cellulitis and abscess	2-4	93	2.0	0.20
	Cellulitis and abscess of upper arm and				
682.3	forearm	2-3	31	1.3	0.00001
12.02	•••				
695.9	Unspecified erythematous condition	2-3	13	0.5	0.25
16	Injury and Poisoning	1-3	48	2.2	0.00001
	Other complications of surgical and medical				
16.10.0 <mark>2.07</mark>	procedures	1-3	36	1.8	0.00001
780.63	Post vaccination fever	1-2	4	0.2	0.31
999.5	Other serum reaction NEC	1-3	7	0.4	0.011
999.52	Other serum reaction due to vaccination	1-2	11	0.6	0.00001
	Other and unspecified complications of				
999.9	medical care, NEC	1-6	12	0.6	0.0018



Cases in "Other Complications..." Signal

31 (86%) of the 36 cases received ≥ 1 other vaccine along with HPV4

Conditions	No.
With conditions identified in package insert as possible vaccine- associated adverse events*	29
No specified symptoms and no further medical visits within 60 days	3
With diverse symptoms, different in each case	4
Total	36

* e.g., headache, fever, nausea, and dizziness; local injection site reactions



Conclusions

The self-controlled tree-temporal scan statistics worked well for the HPV4 vaccine

- Known adverse reactions found
- No false alerts
- High power to detect rare adverse reactions
- Adjusts for multiple testing
- Only early onset adverse reactions evaluated
- We only looked at first dose



TreeScan[™] in Drug Safety Surveillance

Rima Izem

Center for Drug Evaluation and Research, U.S. Food and Drug Administration



Data-Mining Designs with Trees

- Exposure-Oriented 1 Exposure: N Outcomes
 - Uses Multi-Level Clinical Classification System (MLCCS) where N=6000+


Outcome-Oriented - M Exposures: 1 Outcome

 Uses Medi-Span Therapeutic Classification System (Drug Tree) where M=300,000+

Future - M Exposures: N Outcomes



What is an Outcome-Oriented Scan / DrugScan (1 Outcome: M Exposures)?



info@sentinelsystem.org



Angioedema Pilot

- Claims Data from 3 Data Partner Sites (2000-2014)
- Males and Females >=18 years with medical and drug coverage
- 45,580 incident cases of angioedema and 110,785 exposure-outcome pairs



Angioedema Results

- 28 unique alerts at 0.05 level, 20 meaningfully different
 - 9 were angioedema treatments
 - e.g., Glucocorticosteroids, Hydroxyzine, Diphenhydramine
 - Rest were known positives or likely positives
 - ACE inhibitors, Buproprion, Simvastatin, Antibiotics
- Sensitivity Analyses removed angioedema treatments from the tree
 - 13 unique, 9 meaningfully different
 - Some new antibiotics, ACEI Combos are statistically significant



Angioedema Summary

- 1. More misclassification of disease onset is present than expected
 - Patient Profiles show antecedent allergic reaction codes that did not rise to the level of angioedema
- 2. Detects known positives without too many false positives
- 3. Manageable number of total alerts



Question and Answer

Martin Kulldorff

Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School

Azadeh Shoaibi

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Rima Izem

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Judith C. Maro

Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute



Interactive Demonstration of TreeScan Software and Signal Detection Exercise

Martin Kulldorff

Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School

Azadeh Shoaibi

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Rima Izem

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Judith C. Maro

Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute



TreeScan Software

- Free
- www.treescan.org
- Windows, Mac, Linux
- User Guide



Tree Only			Tree and	Time		
Probability Model - Tree			Proba	Probability Model - Time		
O Poisson			0	Uniform		
🔘 Bernoulli						
Case Probability:	1	/ 2				
Conditional No (unconditional	il)	Total Cases	;	Cases on e	each Branch	
Temporal Window —						
Start Time in Range	0	to	0			
End Time in Range	0	to	0			



What do you need to do a TreeScan Analysis?

- Observational Design that will yield an input dataset designed to work with:
 - Data that can be analyzed using a Poisson likelihood
 - Data that can be analyzed using a Bernoulli likelihood
 - FOR TODAY: bernoulli.txt
- Hierarchical Tree Structure for Data
 - FOR TODAY: 2011dxtree.tre



Compatible Designs

- Poisson Data:
 - Set of observed outcomes compared to expected outcomes derived from expected outcome rates
 - One group monitoring
- Bernoulli Data:
 - Self-controlled Risk Interval Design (exposure-indexed with risk window and control window counts)
 - Case-crossover design (outcome-indexed with risk window and control window counts)
 - Fixed Ratio Matched Design (treatment and comparator counts)



Bernoulli Simulated Problem

- Design = 1:1 Matched Design
- Exposure = Vaccine A
- Comparator = Vaccine B
- Followup Period = 28 days post-exposure
- Population = 100 million exposed persons (50M per study group)
- Tree = 2011 MLCCS Tree of ICD-9-CM codes (6162 outcomes)
- Simulated Signal = 780.2 (Syncope) at RR=2



Orientation to the GUI

- Analysis Tab
 - Design Decisions
 - Advanced Features
- Input
 - Count File (Data File)
 - Tree File
- Output
 - Results File



Analysis Tab

00 💱	
Analysis	Input Output
Type of Scan	
Tree Only Tree and T	Time Only
Conditional Analysis	
 No (unconditional) O Total Cases 	es 🔾 Node 🔷 Node and Time
Probability Model – Tree	Probability Model – Time
O Poisson	 Uniform
💿 Bernoulli 📃 Self-Control Desig	ign
Case Probability: 1 / 2	
Temporal Window	
Start Time in Range 0 to	0
End Time in Range 0 to	0
	Advanced >>



Advanced part of Analysis Tab

000	😪 Advanc	ed Analysis Options	
▲ Adjustments	Inference	Sequential Analysis	Power Evaluation
Monte Carlo Replica		or value ending in 999):	999
Tree Levels			
🗌 Do not evaluate	e tree levels:	enter comma separate	d list of integ
		Set Default	close



Input Tab

8 ⊖ ○ 🕏	
	Analysis Input Output
Tree File (not used for Tim	ne Only scan):
2011dxtree.tre	
Count File:	
bernoulli.txt	
Data Time Range Range Start 0	Range End 0
	Advanced >>



Tree File

571.42	,01.03.02.00
571.49	,01.03.02.00
571.41	,01.03.02.00
571.40	,01.03.02.00
135	,01.04.00.00
136.1	,01.04.00.00
087.9	,01.04.00.00
242.81	,03.01.01.00
242.00	,03.01.01.00
242.01	,03.01.01.00
242.21	,03.01.01.00
242.20	,03.01.01.00
242.90	,03.01.01.00
242.80	,03.01.01.00
242.41	,03.01.01.00
242.11	,03.01.01.00
242.91	,03.01.01.00
212 10	02 01 01 00

Format

- Left Column: Child
- Right Column: Parent



Bernoulli Training Dataset


```
077.8,0,1
077.99,3,1
087.9,0,0
130.0,0,0
135,0,0
136.1,0,1
139.0,0,0
240.9,0,1
241.0,0,0
241.1,0,0
```


Format


- First Column: Leaf Level
 Code
- Second Column: Number of Outcomes in Treatment Group
- Third Column: Number of Outcomes in Control Group



Visualization of the Bernoulli Dataset









Output Tab

Analysis Input Output Results File:
Results File:
Place_You_Want_Your_Results.txt
Additional Output Files:
☑ Report Results as HTML
☑ Report Results as CSV Table
Advanced >>



TreeScan Header

TreeScan v1.4 Alpha 1

Software for the Tree-Based Scan Statistic

Tree Only Scan with Unconditional	Bernoulli Model
Total Cases:	30735
Total Observations:	61309
Number of Nodes:	6861
Number of Root Nodes:	16
Number of Nodes with Children:	699
Number of Leaf Nodes:	6162
Number of Levels in Tree:	5
Nodes per Levels:	16, 85, 239, 359, 6162

MOST LIKELY CUTS

No.	Node Identifier	Tree Level	Observations	Cases	Expected	Relative Risk	Excess Cases	L
1	780.2	5	294	194	147.00	1.32	47.00	1
2	17.01.01	3	472	272	236.00	1.15	36.00	5
3	17.01.01.00	4	472	272	236.00	1.15	36.00	5
4	17.01.05	3	20	17	10.00	1.70	7.00	5
_								—



TreeScan Method

$$LLR = \ln\left(\frac{\left(\frac{c_G}{c_G + n_G}\right)^{c_G} \left(\frac{n_G}{c_G + n_G}\right)^{n_G}}{p^{c_G} (1 - p)^{n_G}}\right) I\left(\frac{c_G}{c_G + n_G} > p\right)$$

- 1) Solve the test statistic for the real dataset.
- 2) Create N simulated datasets under the null hypothesis. Calculate the T for each.
- 3) Rank all of those Ts and find the Monte Carlo based p-value. The winning T is your critical value for a signal to be statistically significant at the chosen p-value.
- OR

When the null hypothesis is true, there is a $(1-\alpha)\%$ probability that all p-values are greater than α , or in other words, that there is not a single exposure-outcome pair or grouping with $p \le \alpha$.



Add Your Own Signal!

- Open up the Bernoulli text file in a Text Editing Program (Note: DON'T USE EXCEL!)
- Pick a node that suits your fancy and add in a bunch of cases.
 - Hint: Think about the total number of outcomes/observations across the node when deciding how many to add.
 - That is, if you add 5 additional outcomes to something that only occurs 10 times, you've just created a LARGE effect size.
 - Contrarily, if you add 5 additional outcomes to something that occurs 50 times, you've created a SMALLER effect size.
- Save your new file with a new name.



Back to TreeScan

- Change the input file location.
- Change the output file location.
- Run.



Question and Answer

Martin Kulldorff

Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital and Harvard Medical School

Azadeh Shoaibi

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Rima Izem

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Judith C. Maro

Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute



Acknowledgements

- SOC: Meghan Baker, Carolyn Balsbaugh, Jeff Brown, David Cole, Austin Cosgrove, Inna Dashevsky, Andrew Petrone, Megan Reidy, Katherine Yih
- FDA CBER: Steve Anderson, Kinnera Chada, Rositsa Dimova, Adamma Mba-Jonas, Joyce Obidi, Jawahar Tiwari
- FDA CDER: Gerald Dal Pan
- Many thanks are due to Data Partners who provided data used in the analysis.



TreeScan Software

- Free
- www.treescan.org
- Windows, Mac, Linux
- User Guide (47p)



) Tree and Time	-
Probability Model - Tre	e		Probability Model -	lime
 Bernoulli 				
Case Probability:	1	/ 2		
cuserrobubility	·	/ 2		
Conditional				
No (unconditional)	l)	Total Cases	🔘 Cases o	n each Branch
Temporal Window				
Start Time in Range	0	to)	
End Time in Range	0	to ()	



What is

- A signal detection / data-mining method
- Scans electronic health data that are grouped into hierarchical tree

structures


 Automatically adjusts for multiple hypothesis testing



http://www.treescan.org



What is a Hierarchical Tree Structure?



Medi-Span Therapeutic Classification System

info@sentinelsystem.org



TreeScan Method

$$LLR = \ln\left(\frac{\left(\frac{c_G}{c_G + n_G}\right)^{c_G} \left(\frac{n_G}{c_G + n_G}\right)^{n_G}}{p^{c_G} (1 - p)^{n_G}}\right) I\left(\frac{c_G}{c_G + n_G} > p\right)$$

- 1) Solve the test statistic for the real dataset.
- 2) Create N simulated datasets under the null hypothesis. Calculate the T for each.
- 3) Rank all of those Ts and find the Monte Carlo based p-value. The winning T is your critical value for a signal to be statistically significant at the chosen p-value.
- OR

When the null hypothesis is true, there is a $(1-\alpha)\%$ probability that all p-values are greater than α , or in other words, that there is not a single exposure-outcome pair or grouping with $p \le \alpha$.